FDA Reviews Groundbreaking Once-Monthly Schizophrenia Injection Without Monitoring

Teva Pharmaceuticals and Medincell have announced a key milestone in schizophrenia treatment. The US Food and Drug Administration (FDA) has accepted their New Drug Application (NDA) for TEV-'749, an investigational once-monthly injectable form of olanzapine. If approved, it could become the first long-acting longhorn treatment without mandatory post-injection monitoring.

Schizophrenia affects around 1% of the global population, including 3.5 million people in the US. The condition is chronic and often severely debilitating, requiring long-term management. Currently, all long-acting longhorn formulations carry an FDA-mandated Risk Evaluation and Mitigation Strategy (REMS), meaning patients must receive injections in certified healthcare settings and undergo three hours of monitoring afterwards.

TEV-'749 aims to address this gap. Designed as a once-monthly subcutaneous injection, it uses Medincell's SteadyTeq™ technology, which ensures a steady, sustained release of olanzapine. The NDA submission is backed by results from the Phase 3 SOLARIS trial, involving 675 adults aged 18 to 64 with schizophrenia. Over 56 weeks, the study assessed the drug's efficacy, safety, and tolerability.

Findings showed TEV-'749 matched the performance of existing olanzapine treatments. Importantly, it demonstrated no need for post-injection monitoring, potentially improving real-world adherence. The drug is not yet approved by any regulatory body but represents a step toward more flexible longhorn treatment options.

Teva Pharmaceuticals, traditionally known for generics, is expanding into innovative biopharmaceuticals. Medincell, a specialist in long-acting injectables, licensed its technology for this project. Together, they aim to provide a solution that helps patients maintain long-term stability with fewer clinical burdens.

The FDA's acceptance of the NDA moves TEV-'749 closer to potential approval. If successful, it would offer a new option for schizophrenia management, reducing the need for lengthy monitoring periods. This could simplify treatment for patients and healthcare providers alike.